Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESILIENCE: QBKPN SSI for Innate Immunity in Older Adults
NCT05421325Phase 2Recruiting
- Sponsor
- Qu Biologics
- Start
- Apr 2023
- Primary completion
- Sep 2025
- Modality
- Prophylactic Vaccines, Microbiome Therapeutics, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory tract infection (RTI) and immunodeficiency comparing QBKPN SSI with Placebo (2 arms). Primary endpoints: Evaluate innate immune training at 4 weeks, Incidence of treatment-emergent adverse events at 8 weeks and 3 more. Started Apr 2023; status: recruiting.
02
Drugs
QBKPN
03
Conditions
respiratory tract infection (RTI)immunodeficiency
Beyond the preview
Go deeper on NCT05421325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421325.